| Literature DB >> 30803294 |
Xiao-Hong Gu1, Chao-Jie He2, Liang Shen2, Bin Han3.
Abstract
Background Myocardial infarction with nonobstructive coronary arteries ( MINOCA ) occurs in ≈10% of all patients with myocardial infarction. Studies on effects of depression on MINOCA outcomes are lacking. Therefore, the aim of this study was to examine the association of depression with clinical outcomes in Chinese patients with MINOCA . Methods and Results We conducted a prospective cohort study of 633 participants with MINOCA and followed up for 3 years. End points were defined as all-cause mortality and cardiovascular events. Diagnosis of depression was ascertained using the psychiatric interview based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). During the follow-up period, all-cause death occurred in 93 individuals and cardiovascular events developed in 170 individuals. Kaplan-Meier curves showed a significant association of depression with all-cause mortality (log-rank P<0.001) and cardiovascular events (log-rank P<0.001). Multiple Cox regression identified the new diagnosis of depression as an independent prognostic factor for all-cause mortality as well as cardiovascular events (adjusted hazard ratio, 7.250; 95% CI, 4.735-11.100; P<0.001; and hazard ratio, 3.411; 95% CI , 2.490-4.674; P<0.001, respectively). Conclusions The new diagnosis of depression at the time of myocardial infarction is associated with increased risk of adverse clinical outcomes in patients with MINOCA.Entities:
Keywords: cardiac disease; depression; outcome
Mesh:
Year: 2019 PMID: 30803294 PMCID: PMC6474919 DOI: 10.1161/JAHA.118.011180
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics of the Study Cohort Stratified by Depression
| Characteristics | Not Depressed (n=467) | Depressed (n=167) |
|
|---|---|---|---|
| Demographics | |||
| Age, mean±SD, y | 64.4±13.0 | 64.0±11.1 | 0.699 |
| Female sex, n (%) | 287 (61.5) | 92 (55.4) | 0.173 |
| Risk factors, n (%) | |||
| Current smoking | 90 (19.3) | 28 (16.9) | 0.494 |
| Hypertension | 234 (50.1) | 84 (50.6) | 0.913 |
| Diabetes mellitus | 85 (18.2) | 33 (19.9) | 0.633 |
| Hyperlipidemia | 141 (30.2) | 54 (32.5) | 0.575 |
| Electrocardiographic changes on admission, n (%) | |||
| ST‐segment elevation | 74 (15.8) | 26 (15.7) | 0.956 |
| Medications at discharge, n (%) | |||
| Antiplatelets | 423 (90.6) | 153 (92.2) | 0.539 |
| β Blockers | 387 (82.9) | 141 (82.9) | 0.538 |
| RAAS inhibitors | 322 (69.0) | 107 (64.5) | 0.287 |
| Statins | 389 (83.3) | 133 (80.1) | 0.355 |
| Outcomes, n (%) | |||
| All‐cause mortality | 56 (12.0) | 37 (22.3) | 0.001 |
| Cardiovascular events | 108 (23.1) | 62 (37.3) | <0.001 |
RAAS indicates renin‐angiotensin‐aldosterone system.
Figure 1Cumulative event‐free survival (Kaplan‐Meier curves) for outcomes (all‐cause mortality [A] and cardiovascular events [B]) in patients with and without depression.
Multiple Cox Regression of Variables Influencing All‐Cause Mortality
| Variables | HR (95% CI) |
|
|---|---|---|
| Age, y | 1.015 (0.997–1.034) | 0.099 |
| Female sex | 1.236 (0.813–1.878) | 0.321 |
| Current smoking | 0.700 (0.411–1.190) | 0.187 |
| Hypertension | 1.079 (0.713–1.633) | 0.719 |
| Diabetes mellitus | 1.290 (0.721–2.311) | 0.391 |
| Hyperlipidemia | 0.981 (0.622–1.546) | 0.933 |
| ST‐segment elevation | 5.643 (1.373–23.188) | 0.016 |
| Antiplatelets | 0.903 (0.404–2.021) | 0.805 |
| β Blockers | 0.809 (0.454–1.442) | 0.472 |
| RAAS inhibitors | 0.472 (0.258–0.862) | 0.015 |
| Statins | 0.398 (0.259–0.614) | <0.001 |
| Depression | 7.250 (4.735–11.100) | <0.001 |
HR indicates hazard ratio; RAAS, renin‐angiotensin‐aldosterone system.
Multiple Cox Regression of Variables Influencing Cardiovascular Events
| Variables | HR (95% CI) |
|
|---|---|---|
| Age, y | 1.007 (0.995–1.020) | 0.260 |
| Female sex | 1.157 (0.852–1.573) | 0.350 |
| Current smoking | 0.887 (0.597–1.317) | 0.551 |
| Hypertension | 0.920 (0.677–1.249) | 0.592 |
| Diabetes mellitus | 0.776 (0.537–1.121) | 0.177 |
| Hyperlipidemia | 1.014 (0.725–1.418) | 0.935 |
| ST‐segment elevation | 2.591 (1.348–4.979) | 0.004 |
| Antiplatelets | 1.089 (0.642–1.847) | 0.753 |
| β Blockers | 0.941 (0.617–1.435) | 0.777 |
| RAAS inhibitors | 0.584 (0.393–0.869) | 0.008 |
| Statins | 0.496 (0.360–0.681) | <0.001 |
| Depression | 3.411 (2.490–4.674) | <0.001 |
HR indicates hazard ratio; RAAS, renin‐angiotensin‐aldosterone system.